Parmax Pharma Ltd. benchmarking: Perfomance to industry peers

Financial

	Parmax Pharma	Beryl Drugs	Unjha Formulations
Operational Metrics
Financials
5 yr Average ROE	-1068.03 %	3.64 %	10.34 %
5yr average Equity Multiplier	29.23	2.12	1.62
5yr Average Asset Turnover Ratio	1.05	1.19	3.51
5yr Avg Net Profit Margin	-11.29 %	1.13 %	1.88 %
Price to Book	0.0	1.27	2.76
P/E	0.0	50.65	11.23
5yr Avg Cash Conversion Cycle	-92.25 Days	-589.78 Days	18.8 Days
Inventory Days	69.37 Days	36.09 Days	28.57 Days
Days Receivable	20.01 Days	112.55 Days	41.04 Days
Days Payable	296.94 Days	964.25 Days	53.92 Days
5yr Average Interest Coverage Ratio	-0.77	1.91	17.56
5yr Avg ROCE	-14.3 %	7.2 %	19.44 %
5yr Avg Operating Profit Margin	2.43 %	6.72 %	3.19 %
5 yr average Debt to Equity	10.96	0.59	0.0
5yr CAGR Net Profit	n/a	19.3 %	32.6 %
5yr Average Return on Assets	-9.05 %	1.98 %	6.62 %
Shareholdings
Promoter Holding	30.8 %	26.38 %	36.92 %
Share Pledged by Promoters	0.0	0.0	0.0
Change in Promoter Holding (3 Yrs)	0.0	1.46 %	0.0
Change in Mutual Fund Holding (3 Yrs)	0.0	0.0	0.0